Integral Diagnostics Limited (ASX:IDX): What Do FY26 Earnings and Imaging Integration Reveal?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Integral Diagnostics Limited (ASX:IDX): What Do FY26 Earnings and Imaging Integration Reveal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Integral Diagnostics (ASX:IDX) recorded AUD 788.7 million of FY26 Revenue and other income.
Operating EBITDA increased 30.3% to AUD 164.8 million during FY26.
Operating NPAT reached AUD 47.4 million; statutory NPAT totalled AUD 22.0 million.
A fully franked final Dividend of six Australian cents per share was declared.

Integral Diagnostics Limited (ASX:IDX) operates diagnostic imaging clinics across Australia and New Zealand, providing radiology services to patients and referring clinicians. On 12 November 2026, Integral Diagnostics shares traded at AUD 1.703, up 0.15% during the session. Its FY26 results provide an updated picture of the combined imaging Business as management continues operational integration following the Capitol Health transaction. Financial reporting highlights the distinction between ordinary operating performance and the costs associated with the enlarged network.

Diagnostic Imaging Operations and Network

Integral Diagnostics (ASX:IDX) delivers medical imaging through clinics and specialist radiologists. Its services include modalities used to diagnose and monitor medical conditions, with clinic capacity, reporting turnaround times and the availability of clinical staff affecting service delivery. The business also uses teleradiology, under which medical images can be interpreted remotely. Operating results reflect the mix of scans performed, the availability of radiologists and the reimbursement arrangements applicable to imaging services. The company is exposed to the Australian and New Zealand diagnostic markets rather than pharmaceutical development or medical-device manufacturing.

FY26 Results and Integration Activity

In August 2026, Integral Diagnostics (ASX:IDX) reported FY26 revenue and other income of AUD 788.7 million, an increase of 25.6%. Operating Earnings before interest, tax, Depreciation and Amortisation (EBITDA) rose 30.3% to AUD 164.8 million, while the operating EBITDA Margin reached 20.9%. The figures include a different contribution from acquired activities across reporting periods, which matters when evaluating growth. Management also reported continuing work on integrating the Capitol network, with systems, clinician recruitment, site operations and procurement among the relevant execution areas. Integration costs should not be confused with ongoing operating expenditure.

Profit, Cash Flow and Dividends

Integral Diagnostics (ASX:IDX) reported operating net profit after tax of AUD 47.4 million, up 50.1%, compared with statutory net profit after tax of AUD 22.0 million. The difference reflects adjustments that include transaction, restructuring and integration items. Operating free cash flow reached AUD 106.4 million, while net Debt relative to operating EBITDA was 2.3 times at financial year-end. The board declared a fully franked final dividend of six cents per share, taking the total FY26 dividend to 9.3 cents per share. These measures offer different perspectives on profitability, cash generation and financing capacity.

Risks and Operational Monitoring

The imaging industry depends on availability of radiologists, clinical staffing levels, referrals, scanner utilisation and appropriate service reimbursement. For Integral Diagnostics (ASX:IDX), bringing acquired clinics onto shared operating practices adds organisational and technology requirements. Additional sites and equipment can require Capital spending before delivering mature utilisation. Cost inflation, equipment downtime and patient access can also influence margins. Reported percentage growth should therefore be read alongside clinic mix, integration spending and the movement from operating earnings to statutory profit.

What to Watch Next

Further company disclosures can clarify whether integration expenditure moderates, whether imaging volumes and reporting productivity change, and how teleradiology is used across the network. Investors may also monitor operating cash flow, net debt, specialist recruitment and the performance of newer clinics. The FY26 results establish a reference point for comparing subsequent revenue, operating EBITDA margin and statutory profit. Any updated guidance should be assessed against the actual timing of clinic Investment and staffing requirements.

Key Insights

Integral Diagnostics (ASX:IDX) reported higher FY26 revenue and operating earnings, with an operating EBITDA margin of 20.9%. Statutory profit remained below operating profit, highlighting the financial effect of integration and other adjustment items. The company’s next disclosures can help establish how efficiently its imaging network converts clinical activity into earnings and cash flow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.